Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Euronext Amsterdam  >  Kiadis Pharma    KDS   NL0011323407

KIADIS PHARMA

(KDS)
  Report  
 SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Euronext Amsterdam
07/17/2019 07/18/2019 07/19/2019 07/22/2019 07/23/2019 Date
5.155(c) 4.95(c) 4.84(c) 4.65(c) 4.624 Last
291 298 471 956 369 292 875 307 158 103 Volume
-2.09% -3.98% -2.22% -3.93% -0.56% Change
More quotes
Financials (EUR)
Sales 2019 0,05 M
EBIT 2019 -37,2 M
Net income 2019 -43,9 M
Finance 2019 32,6 M
Yield 2019 -
Sales 2020 6,12 M
EBIT 2020 -36,8 M
Net income 2020 -47,9 M
Debt 2020 6,00 M
Yield 2020 -
P/E ratio 2019 -2,79x
P/E ratio 2020 -2,80x
EV / Sales2019 2 097x
EV / Sales2020 23,4x
Capitalization 137 M
More Financials
Company
Kiadis Pharma is developing potentially life saving therapies for patients with late-stage blood cancers, who are in need of a transplant, an area of significant need. Kiadis Pharma is building a fully integrated biopharmaceutical company to maximize the potential of ATIR, the company's proprietary... 
More about the company
Surperformance© ratings of Kiadis Pharma
Trading Rating : Investor Rating : -
More Ratings
Latest news on KIADIS PHARMA
07/01KIADIS PHARMA : updates status of marketing authorization application for ATIR10..
AQ
06/28KIADIS PHARMA : updates status of marketing authorization application for ATIR10..
GL
06/24KIADIS PHARMA : Announces Results Annual General Meeting
GL
06/06KIADIS PHARMA : completes acquisition of CytoSen Therapeutics, Inc.
GL
06/04KIADIS PHARMA : to present at upcoming conferences in June 2019
AQ
06/03KIADIS PHARMA : to present at upcoming conferences in June 2019
AQ
06/01KIADIS PHARMA : raises c.EUR 28 million in a private placement of c.3.7 million ..
AQ
05/31KIADIS PHARMA : launches a private placement of new shares to raise approximatel..
AQ
05/31KIADIS PHARMA : raises c.EUR 28 million in a private placement of c.3.7 million ..
GL
05/30KIADIS PHARMA : launches a private placement of new shares to raise approximatel..
GL
More news
Analyst Recommendations on KIADIS PHARMA
More recommendations
Sector news : Biotechnology & Medical Research - NEC
07/22GILEAD SCIENCES : Says Study of GS-6207 Showed HIV Capsid Inhibition Can Lead Vi..
DJ
07/22GILEAD SCIENCES : Licenses Durect's Saber Technology for Injectable HIV Product
DJ
07/19Gilead Licenses Respiratory, Herpes Antiviral Research Programs From Novartis
DJ
07/17GILEAD SCIENCES : Chief Scientific Officer John McHutchison to Leave
DJ
07/16As steep patent cliff looms, Shionogi moves to develop its own U.S. sales sta..
RE
More sector news : Biotechnology & Medical Research - NEC
Chart KIADIS PHARMA
Duration : Period :
Kiadis Pharma Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends KIADIS PHARMA
Short TermMid-TermLong Term
TrendsBearishBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 6
Average target price 13,67  €
Last Close Price 4,65  €
Spread / Highest target 352%
Spread / Average Target 194%
Spread / Lowest Target 7,53%
EPS Revisions
Managers
NameTitle
Arthur K. Lahr Chief Executive Officer
Mark A. Wegter Chairman-Supervisory Board
Jan Feijen Chief Operations Officer
Scott A. Holmes Chief Financial Officer
Andrew S. Sandler Chief Medical Officer
Sector and Competitors
1st jan.Capitalization (M$)
KIADIS PHARMA-39.06%154
IQVIA HOLDINGS INC34.52%30 740
LONZA GROUP34.08%25 623
CELLTRION, INC.--.--%20 071
INCYTE CORPORATION28.50%17 271
EXACT SCIENCES CORPORATION82.06%14 835